Takeda links with CellCentric on epigenetic target
This article was originally published in Scrip
Executive Summary
Takedahas signed an agreement with CellCentric for the validation of a cancer-related protein identified by the UK firm as a possible therapeutic target. Takeda also has an option to acquire rights to the inhibitor development programme related to the target. CellCentric has a network of relationships with facilities conducting research into epigenetic disease mechanisms, through which it identifies targets for the generation of novel small-molecule drugs. Its investors include the Rainbow Seed Fund, which is funded by the UK Office of Science and Innovation to support the commercialisation of public research.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.